tacrolimus pharmaswiss 1 mg capsule, hard
tacrolimus pharmaswiss 5 mg capsule, hard
dorzolamide + timolol pharmaswiss 20 mg/ml + 5 mg/ml, eye drops solution
bausch + lomb ireland limited - dorzolamide hydrochloride; timolol maleate - eye drops, solution - 20mg/ml+5 milligram(s)/millilitre - beta blocking agents1); timolol, combinations
dorzolamide pharmaswiss 20 mg/ml eye drops solution
bausch + lomb ireland limited - dorzolamide - eye drops, solution - 20 milligram(s)/millilitre - carbonic anhydrase inhibitors; dorzolamide
increlex
ipsen pharma - mecasermin - laron syndrome - pituitary and hypothalamic hormones and analogues - for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary igfd).severe primary igfd is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (igf-1) levels below the 2.5th percentile for age and gender and;growth hormone (gh) sufficiency;exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signalling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment. it is recommended to confirm the diagnosis by conducting an igf-1 generation test.
ramipril/amlodipine aristo 10 mg/10 mg kapsel, hård
ramipril/amlodipine aristo 5 mg/5 mg kapsel, hård
ramipril/amlodipine aristo 2,5 mg/5 mg kapsel, hård
ramipril/amlodipine aristo 5 mg/10 mg kapsel, hård
ramipril/amlodipine aristo 10 mg/5 mg kapsel, hård